** Shares of medical device maker Dexcom DXCM.O fall 3.9% to $74.82 premarket
** Late on Friday, DXCM said it had received a warning letter from the U.S. FDA following inspections of its two manufacturing facilities in San Diego, California and Mesa, Arizona
** Company said it has already submitted responses to the so-called "Form 483" and is currently preparing a written response
** A Form 483 is an agency report that includes "observations" made by FDA inspectors regarding practices or conditions they find "objectionable
** Stock has fallen 41.6% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.